Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

about

Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy.Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.

P2860

Q47579204-65B71A9D-CB98-4130-8C69-0D1288E701E1 Q55410018-8F9D1632-DDBD-48CC-8C12-9C0E855E3F6A

P2860

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

Item

http://www.wikidata.org/entity/Q38714348

description

2016 nî lūn-bûn

@nan

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

@en

type

Item

label

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

@en

prefLabel

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

@en

P1476

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

@en

P2093

Mark V Sherrid

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence

Pharmacogenetics, drug-metabolizing enzymes, and clinical practice

Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil

Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy

The failing heart--an engine out of fuel

Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy.

Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy

Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.

P304

52-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2174/1573403X1201160126125403

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark V Sherrid

P5008

ScienceSource

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26818487

http://www.w3.org/2001/XMLSchema#string

P921

hypertrophic cardiomyopathy

P932

4807719

http://www.w3.org/2001/XMLSchema#string

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

about

P2860

P2860

Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932